002166 莱茵生物
已收盘 11-20 15:00:00
资讯
新帖
简况
莱茵生物:罗汉果提取物、甜叶菊提取物等核心产品正集中生产
证券之星 · 11-10
莱茵生物:罗汉果提取物、甜叶菊提取物等核心产品正集中生产
莱茵生物(002166)11月5日主力资金净卖出1759.12万元
证券之星 · 11-06
莱茵生物(002166)11月5日主力资金净卖出1759.12万元
莱茵生物:以成为全球值得信赖的天然健康产品服务商为愿景
证券之星 · 11-05
莱茵生物:以成为全球值得信赖的天然健康产品服务商为愿景
莱茵生物(002166)2026年三季报简析:净利润同比下降10.29%,应收账款上升
证券之星 · 10-31
莱茵生物(002166)2026年三季报简析:净利润同比下降10.29%,应收账款上升
莱茵生物:公司前三季度营业收入同比下降主要系部分单品因市场需求阶段性变化导致销量出现下滑
证券之星 · 10-30
莱茵生物:公司前三季度营业收入同比下降主要系部分单品因市场需求阶段性变化导致销量出现下滑
股市必读:莱茵生物三季报 - 第三季度单季净利润同比下降79.52%
证券之星 · 10-30
股市必读:莱茵生物三季报 - 第三季度单季净利润同比下降79.52%
图解莱茵生物三季报:第三季度单季净利润同比下降79.52%
证券之星 · 10-29
图解莱茵生物三季报:第三季度单季净利润同比下降79.52%
莱茵生物:核心天然甜味剂产品为甜叶菊提取物、罗汉果提取物
证券之星 · 10-23
莱茵生物:核心天然甜味剂产品为甜叶菊提取物、罗汉果提取物
莱茵生物(002166)10月9日主力资金净买入151.10万元
证券之星 · 10-12
莱茵生物(002166)10月9日主力资金净买入151.10万元
公司问答丨莱茵生物:公司甜菊糖苷RM2的国内新食品添加剂认证处于审核阶段
格隆汇 · 09-15
公司问答丨莱茵生物:公司甜菊糖苷RM2的国内新食品添加剂认证处于审核阶段
莱茵生物:甜菊糖苷RM2已通过美国FDA GRAS认证
证券之星 · 09-15
莱茵生物:甜菊糖苷RM2已通过美国FDA GRAS认证
9月14日增减持汇总:莱茵生物等8股拟减持,当日暂无A股上市公司拟增持(表)
新浪证券 · 09-14
9月14日增减持汇总:莱茵生物等8股拟减持,当日暂无A股上市公司拟增持(表)
莱茵生物:坚持以自主研发为核心
证券之星 · 09-10
莱茵生物:坚持以自主研发为核心
莱茵生物:公司作为全球天然甜味剂的主要供应商之一
证券之星 · 09-10
莱茵生物:公司作为全球天然甜味剂的主要供应商之一
莱茵生物:甜菊糖苷RM2及生物多糖认证均处于审核阶段
证券之星 · 09-10
莱茵生物:甜菊糖苷RM2及生物多糖认证均处于审核阶段
莱茵生物:9月1日接受机构调研,包括知名机构正圆投资的多家机构参与
证券之星 · 09-07
莱茵生物:9月1日接受机构调研,包括知名机构正圆投资的多家机构参与
莱茵生物(002166)披露2026年半年度报告,8月31日股价下跌1.59%
证券之星 · 08-31
莱茵生物(002166)披露2026年半年度报告,8月31日股价下跌1.59%
莱茵生物(002166)2026年中报简析:营收净利润同比双双增长,应收账款上升
证券之星 · 08-30
莱茵生物(002166)2026年中报简析:营收净利润同比双双增长,应收账款上升
莱茵生物(002166)6月30日股东户数3.7万户,较上期减少5.16%
证券之星 · 08-29
莱茵生物(002166)6月30日股东户数3.7万户,较上期减少5.16%
图解莱茵生物中报:第二季度单季净利润同比增长91.75%
证券之星 · 08-29
图解莱茵生物中报:第二季度单季净利润同比增长91.75%
暂无数据
公司概况
公司名称:
桂林莱茵生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2007-09-13
主营业务:
桂林莱茵生物科技股份有限公司的主营业务是天然健康功能性成分的研发与生产。公司的主要产品是罗汉果提取物、甜叶菊提取物、茶叶提取物及其他植物提取物、甜菊糖苷RM系列产品、左旋β-半乳葡聚糖。
发行价格:
9.89
{"stockData":{"symbol":"002166","market":"SZ","secType":"STK","nameCN":"莱茵生物","latestPrice":5.47,"timestamp":1795158204000,"preClose":5.77,"halted":0,"volume":8080290,"delay":0,"changeRate":-0.052,"floatShares":739000000,"shares":742000000,"eps":0.1833,"marketStatus":"已收盘","change":-0.3,"latestTime":"11-20 15:00:00","open":5.7,"high":5.71,"low":5.46,"amount":44871000,"amplitude":0.0433,"askPrice":5.47,"askSize":52,"bidPrice":5.46,"bidSize":662,"shortable":0,"etf":0,"ttmEps":0.1833,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795397400000},"marketStatusCode":5,"adr":0,"adjPreClose":5.77,"symbolType":"stock","openAndCloseTimeList":[[1795138200000,1795145400000],[1795150800000,1795158000000]],"highLimit":6.35,"lowLimit":5.19,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":741609425,"isCdr":false,"pbRate":1.37,"roa":"--","peRate":29.841789,"roe":"2.01%","epsLYR":0.1945,"committee":-0.072771,"marketValue":4057000000,"turnoverRate":0.0109,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-11-23。","floatMarketCap":4040000000},"requestUrl":"/m/hq/s/002166/tweets","defaultTab":"tweets","newsList":[{"id":"2682333352","title":"莱茵生物:罗汉果提取物、甜叶菊提取物等核心产品正集中生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2682333352","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682333352?lang=zh_cn&edition=full","pubTime":"2026-11-10 11:37","pubTimestamp":1794281822,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物11月09日在投资者关系平台上答复投资者关心的问题。甜叶菊,百香果有没有投产,或加大产量提升,美国那边的公司最近发展如何莱茵生物回复:感谢您对公司的关注。公司主要从事天然健康产品的生产经营业务,当前正值罗汉果提取物、甜叶菊提取物等核心产品的集中生产季,公司工厂正全力组织生产,保障来年产品的充足供应。美国工厂生产、公司各项研发工作均按既定计划有序推进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111000014962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK0239","BK0028","BK0168","002166","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681827588","title":"莱茵生物(002166)11月5日主力资金净卖出1759.12万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681827588","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681827588?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:17","pubTimestamp":1793927830,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月5日收盘,莱茵生物报收于6.35元,下跌1.24%,换手率2.31%,成交量17.04万手,成交额1.08亿元。近5日资金流向一览见下表:莱茵生物融资融券信息显示,融资方面,当日融资买入1469.02万元,融资偿还957.35万元,融资净买入511.68万元。莱茵生物主营业务:天然健康产品的生产经营业务,持续专注植物功能性成分提取领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600009573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0174","BK0239","BK0168","002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681097094","title":"莱茵生物:以成为全球值得信赖的天然健康产品服务商为愿景","url":"https://stock-news.laohu8.com/highlight/detail?id=2681097094","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681097094?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:52","pubTimestamp":1793839931,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物11月04日在投资者关系平台上答复投资者关心的问题。投资者提问:您好董秘,请问您对2026全年公司全年营收和净利润有大概统计吗,有没有成为全国甚至全球领先企业的计划莱茵生物回复:您好!莱茵生物以成为全球值得信赖的天然健康产品服务商为愿景,坚持“天然提取+合成生物”双技术路线、国内外双供应链布局,贯彻“大单品 + N”发展策略,致力于打造具备全球竞争力的功能性成分制造企业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500010223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK0239","BK0028","BK0168","002166","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679225234","title":"莱茵生物(002166)2026年三季报简析:净利润同比下降10.29%,应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2679225234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679225234?lang=zh_cn&edition=full","pubTime":"2026-10-31 07:43","pubTimestamp":1793403817,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期莱茵生物发布2026年三季报。截至本报告期末,公司营业总收入12.25亿元,同比下降3.74%,归母净利润6315.41万元,同比下降10.29%。按单季度数据看,第三季度营业总收入3.51亿元,同比下降19.31%,第三季度归母净利润661.1万元,同比下降79.52%。本报告期莱茵生物应收账款上升,应收账款同比增幅达35.99%。去年的净利率为7.48%,算上全部成本后,公司产品或服务的附加值一般。本文数据来源于莱茵生物2026年三季报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100016789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679250484","title":"莱茵生物:公司前三季度营业收入同比下降主要系部分单品因市场需求阶段性变化导致销量出现下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2679250484","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679250484?lang=zh_cn&edition=full","pubTime":"2026-10-30 11:36","pubTimestamp":1793331406,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物(002166)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问:造成公司三季报业绩下降10%是公司的第三季度的主营收入同比少了8400万,请问第三季度主营收入下降是什么原因?莱茵生物回复:您好,公司前三季度营业收入同比下降主要系部分单品因市场需求阶段性变化导致销量出现下滑。公司天然甜味剂业务整体经营稳健。谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000024633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679378712","title":"股市必读:莱茵生物三季报 - 第三季度单季净利润同比下降79.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679378712","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679378712?lang=zh_cn&edition=full","pubTime":"2026-10-30 05:32","pubTimestamp":1793309573,"startTime":"0","endTime":"0","summary":"截至2026年10月29日收盘,莱茵生物报收于6.05元,下跌5.47%,换手率1.57%,成交量11.61万手,成交额7103.7万元。业绩披露要点财务报告2026年前三季度主营收入12.25亿元,同比下降3.74%;归母净利润6315.41万元,同比下降10.29%;扣非净利润4354.52万元,同比下降29.14%。公司公告汇总2026年三季度报告2026年第三季度营业收入为3.51亿元,同比下降19.31%;归母净利润为661.1万元,同比下降79.52%。经营活动产生的现金流量净额为4.79亿元,同比增长38.29%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000007478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679141578","title":"图解莱茵生物三季报:第三季度单季净利润同比下降79.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679141578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679141578?lang=zh_cn&edition=full","pubTime":"2026-10-29 03:44","pubTimestamp":1793216663,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物2026年三季报显示,前三季度公司主营收入12.25亿元,同比下降3.74%;归母净利润6315.41万元,同比下降10.29%;扣非净利润4354.52万元,同比下降29.14%;其中2026年第三季度,公司单季度主营收入3.51亿元,同比下降19.31%;单季度归母净利润661.1万元,同比下降79.52%;单季度扣非净利润-164.64万元,同比下降105.93%;负债率35.22%,投资收益226.15万元,财务费用3120.92万元,毛利率24.18%。财报数据概要请见下图:本文数据来源于莱茵生物2026年三季报,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900003862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677913691","title":"莱茵生物:核心天然甜味剂产品为甜叶菊提取物、罗汉果提取物","url":"https://stock-news.laohu8.com/highlight/detail?id=2677913691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677913691?lang=zh_cn&edition=full","pubTime":"2026-10-23 08:39","pubTimestamp":1792715949,"startTime":"0","endTime":"0","summary":"公司核心天然甜味剂产品为甜叶菊提取物、罗汉果提取物,不同纯度的产品甜度可达蔗糖几十倍至百倍以上,产品热量低,无代谢负担。莱茵生物长期深耕功能性健康成分赛道,以向消费者提供健康产品、赋能大健康产业为长期目标,为全球食品、饮料、调味品等领域客户提供天然减糖原料及定制化配方服务,满足大众控糖的健康需求,助力推动公共健康事业发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300008352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0174","002166","BK0239","BK0168","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674847343","title":"莱茵生物(002166)10月9日主力资金净买入151.10万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674847343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674847343?lang=zh_cn&edition=full","pubTime":"2026-10-12 09:07","pubTimestamp":1791767244,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月9日收盘,莱茵生物报收于7.3元,上涨4.89%,换手率3.31%,成交量24.41万手,成交额1.75亿元。近5日资金流向一览见下表:莱茵生物融资融券信息显示,融资方面,当日融资买入3423.58万元,融资偿还1088.58万元,融资净买入2335.0万元,连续3日净买入累计3775.0万元。莱茵生物主营业务:天然健康产品的生产经营业务,持续专注植物功能性成分提取领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200002899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0168","BK0174","BK0028","002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667617302","title":"公司问答丨莱茵生物:公司甜菊糖苷RM2的国内新食品添加剂认证处于审核阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617302","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667617302?lang=zh_cn&edition=full","pubTime":"2026-09-15 15:54","pubTimestamp":1789458841,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","002166","BK0046","BK0168","159151","BK0028","BK0174"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667568692","title":"莱茵生物:甜菊糖苷RM2已通过美国FDA GRAS认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2667568692","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667568692?lang=zh_cn&edition=full","pubTime":"2026-09-15 08:45","pubTimestamp":1789433111,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物09月14日在投资者关系平台上答复投资者关心的问题。莱茵生物回复:您好,公司甜菊糖苷RM2已通过美国FDA GRAS认证,具备海外销售资质;国内新食品添加剂认证处于审核阶段。目前,公司合成生物业务已完成产能、研发、销售全链条布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500006637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","002166","BK0046","BK0028","BK0174","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667661424","title":"9月14日增减持汇总:莱茵生物等8股拟减持,当日暂无A股上市公司拟增持(表)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667661424","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667661424?lang=zh_cn&edition=full","pubTime":"2026-09-14 21:52","pubTimestamp":1789393920,"startTime":"0","endTime":"0","summary":"9月14日盘后,据不完全统计,包括美年健康、誉衡药业、莱茵生物、奥浦迈、江河集团、东来技术、山东玻纤、楚天龙等在内的8家A股上市公司披露拟减持情况,当日暂无A股上市公司披露拟增持情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-inirveas7272654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03188","02846","82846","BK0174","03130","159982","83188","BK0028","BK0046","BK1147","07233","BK0239","BK0168","002166","399300","83130","02827"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666556429","title":"莱茵生物:坚持以自主研发为核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2666556429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666556429?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:54","pubTimestamp":1789001654,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物09月09日在投资者关系平台上答复投资者关心的问题。我们在上海搭建了复合型研发平台,核心团队由多名博士牵头,研发布局覆盖食品饮料配方应用、日化应用开发以及合成生物技术攻关三大方向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000007309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0168","BK0239","002166","BK0174"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666055649","title":"莱茵生物:公司作为全球天然甜味剂的主要供应商之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2666055649","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666055649?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:54","pubTimestamp":1789001654,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物(002166)09月09日在投资者关系平台上答复投资者关心的问题。投资者提问:您好,董秘,绿可乐自2026年5月上市以来,累计销量突破60万箱、1440万瓶,年度目标从50万箱直接上调到200万箱,是原计划的四倍,网上流传甜菊糖苷供应商为莱茵生物,能否证实?莱茵生物回复:您好,公司作为全球天然甜味剂的主要供应商之一,近年来持续开拓下游应用市场,与海内外众多品牌客户建立稳定合作,覆盖食品、饮料、调味品、化妆品等赛道。关于下游客户合作情况,您可参考品牌官方公开信息,谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000007312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK0046","002166","BK0168","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666556425","title":"莱茵生物:甜菊糖苷RM2及生物多糖认证均处于审核阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2666556425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666556425?lang=zh_cn&edition=full","pubTime":"2026-09-10 08:54","pubTimestamp":1789001653,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物(002166)09月09日在投资者关系平台上答复投资者关心的问题。投资者提问:公司合成生物业务的甜菊糖苷RM2和生物多糖认证审批是否已中止或终止,久未有消息了?莱茵生物回复:您好, 公司甜菊糖苷RM2的国内新食品添加剂认证、左旋β-半乳葡聚糖的国内新食品原料及美国FDA GRAS认证均处于审核阶段,谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000007308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0168","BK0174","BK0028","002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665115363","title":"莱茵生物:9月1日接受机构调研,包括知名机构正圆投资的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2665115363","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665115363?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:33","pubTimestamp":1788773618,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年9月1日莱茵生物发布公告称公司于2026年9月1日接受机构调研,中信建投杨骥 高畅、源乘投资曾尚、衍复投资张道武、中泰证券田海川、华夏基金胡慧婷 李柄桦、宏利基金刘硕、红土创新基金张豪、民生基金董博、国海富兰克林基金张瑞、金元顺安基金侯斌、正圆投资冯荃晴、睿亿投资吕乐艺参与。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK0028","BK0046","BK0239","BK0168","002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663070952","title":"莱茵生物(002166)披露2026年半年度报告,8月31日股价下跌1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663070952","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663070952?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:31","pubTimestamp":1788175866,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘,莱茵生物报收于6.81元,较前一交易日下跌1.59%,最新总市值为50.5亿元。该股当日开盘6.95元,最高6.95元,最低6.76元,成交额达6606.44万元,换手率为1.31%。近日,公司披露《2026年半年度报告》。总资产为4,809,508,493.04元,较上年度末下降10.64%;归属于上市公司股东的净资产为3,113,463,787.03元,较上年度末下降1.36%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100031274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0028","BK0174","BK0168","002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048241","title":"莱茵生物(002166)2026年中报简析:营收净利润同比双双增长,应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048241?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:23","pubTimestamp":1788042203,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期莱茵生物发布2026年中报。截至本报告期末,公司营业总收入8.73亿元,同比上升4.35%,归母净利润5654.32万元,同比上升48.37%。按单季度数据看,第二季度营业总收入4.27亿元,同比上升8.62%,第二季度归母净利润1402.66万元,同比上升91.75%。本报告期莱茵生物应收账款上升,应收账款同比增幅达43.35%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663012688","title":"莱茵生物(002166)6月30日股东户数3.7万户,较上期减少5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663012688","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663012688?lang=zh_cn&edition=full","pubTime":"2026-08-29 17:13","pubTimestamp":1787994817,"startTime":"0","endTime":"0","summary":"证券之星消息,近日莱茵生物披露,截至2026年6月30日公司股东户数为3.7万户,较3月31日减少2013.0户,减幅为5.16%。在化学制品行业个股中,莱茵生物股东户数高于行业平均水平,截至6月30日,化学制品行业平均股东户数为3.1万户。从股价来看,2026年3月31日至2026年6月30日,莱茵生物区间跌幅为31.87%,在此期间股东户数减少2013.0户,减幅为5.16%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900023507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0168","BK0174","002166","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663187710","title":"图解莱茵生物中报:第二季度单季净利润同比增长91.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663187710","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663187710?lang=zh_cn&edition=full","pubTime":"2026-08-29 02:55","pubTimestamp":1787943337,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物2026年中报显示,上半年度公司主营收入8.73亿元,同比上升4.35%;归母净利润5654.32万元,同比上升48.37%;扣非净利润4519.16万元,同比上升34.13%;其中2026年第二季度,公司单季度主营收入4.27亿元,同比上升8.62%;单季度归母净利润1402.66万元,同比上升91.75%;单季度扣非净利润486.35万元,同比上升299.16%;负债率33.5%,投资收益224.67万元,财务费用2275.7万元,毛利率24.79%。财报数据概要请见下图:本文数据来源于莱茵生物2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900006320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1795317658979,"stockEarnings":[{"period":"1week","weight":-0.0944},{"period":"1month","weight":-0.1762},{"period":"3month","weight":-0.1884},{"period":"6month","weight":-0.3705},{"period":"1year","weight":-0.314},{"period":"ytd","weight":-0.3457}],"compareEarnings":[{"period":"1week","weight":-0.0277},{"period":"1month","weight":-0.0483},{"period":"3month","weight":-0.0951},{"period":"6month","weight":-0.1408},{"period":"1year","weight":-0.1011},{"period":"ytd","weight":-0.1096}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"桂林莱茵生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41528人(较上一季度增加12.15%)","perCapita":"17784股","listingDate":"2007-09-13","address":"广西壮族自治区桂林市临桂区人民南路19号","registeredCapital":"74160万元","survey":" 桂林莱茵生物科技股份有限公司的主营业务是天然健康功能性成分的研发与生产。公司的主要产品是罗汉果提取物、甜叶菊提取物、茶叶提取物及其他植物提取物、甜菊糖苷RM系列产品、左旋β-半乳葡聚糖。","listedPrice":9.89},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"莱茵生物(002166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供莱茵生物(002166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"莱茵生物,002166,莱茵生物股票,莱茵生物股票老虎,莱茵生物股票老虎国际,莱茵生物行情,莱茵生物股票行情,莱茵生物股价,莱茵生物股市,莱茵生物股票价格,莱茵生物股票交易,莱茵生物股票购买,莱茵生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"莱茵生物(002166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供莱茵生物(002166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}